Tic disorder

Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform

Retrieved on: 
Monday, September 26, 2022

Continuing Neuronetics commitment to innovation, this release represents the third TrakStar upgrade in 2022.

Key Points: 
  • Continuing Neuronetics commitment to innovation, this release represents the third TrakStar upgrade in 2022.
  • We continue to innovate our TrakStar platform to be a smarter, better tool, stated Keith J. Sullivan, President, and CEO of Neuronetics Inc.
  • The latest updates can streamline the patient journey by bridging our proprietary PHQ-10 platform with our HIPAA-compliant TrakStar patient data management system making it easier to identify new patients and those needing re-treatment.
  • As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health.

Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle

Retrieved on: 
Friday, September 23, 2022

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Key Points: 
  • HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
  • This historic donation is being made to commemorate the Blue Bird Circle's upcoming centennial anniversary and brings the organization's gifts to Texas Children's to over $25 million which will help advance life-changing neurological research at the Duncan NRI.
  • At Texas Children's Hospital Blue Bird Clinic, Blue Bird volunteers log more than 5,000 hours a year in administrative assistance the equivalent of three full-time employees.
  • The volunteers' time, effort, and donations help support The Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital.

AVESTA KETAMINE AND WELLNESS OPENS THIRD AND NEW LOCATION IN NW WASHINGTON DC

Retrieved on: 
Tuesday, September 20, 2022

WASHINGTON, Sept. 20, 2022 /PRNewswire/ -- The founder of Avesta Ketamine and Wellness, Dr. Ladan Eshkevari is a Professor Emerita at Georgetown University, having retired just this year. Dr Eshkevari's area of training/expertise is Anesthesia and Pain Management, Chronic Stress and Endocrine Physiology and Acupuncture. Dr. Eshkevari has been providing Ketamine and IV vitamin infusions as a Nurse Anesthesiologist in clinical settings for over 25 years.

Key Points: 
  • Avesta, a leading provider of Ketamine infusions and IV Vitamin Therapy announces the opening of their third location.
  • Conveniently located in downtown DC within steps from the Dupont Circle Metro Station, at 1400 16th St, NW Suite 101 Washington DC 20036
    WASHINGTON, Sept. 20, 2022 /PRNewswire/ -- The founder of Avesta Ketamine and Wellness, Dr. Ladan Eshkevari is a Professor Emerita at Georgetown University, having retired just this year.
  • Avesta Ketamine and Wellness, a leader in the Ketamine/Wellness infusion industry opens third location in Washington DC!
  • Avesta is currently running a research protocol comparing Ketamine and IV antioxidants versus Ketamine alone in patients suffering from treatment resistant depression (TRD).

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

Retrieved on: 
Tuesday, September 20, 2022

and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley .

Key Points: 
  • and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley .
  • I am inspired by the work NAMI does for mental health around the country, and I am looking forward to joining forces at the NAMI Silicon Valley walk, said Dr. von Jako.
  • Rovina Nimbalkar, Executive Director of NAMI Santa Clara County, said, We are honored to have Christopher von Jako as our honorary chair for NAMIWalks Silicon Valley and we are excited about our collaboration with BrainsWay.
  • NAMIWalks Silicon Valley is our biggest fundraiser, and after two years we are going to walk in person.

Seoul Relax Week Meditation Conference 2022 to Be Held with the Theme of Counseling Psychology and Mindfulness

Retrieved on: 
Monday, September 19, 2022

The Seoul Relax Week Meditation Conference 2022 , which celebrates its 4th anniversary, will be returned both online and offline on October 1st and 2nd under the theme of Counseling Psychology and Mindfulness at the SETEC Convention Hall and via Zoom webinar.

Key Points: 
  • The Seoul Relax Week Meditation Conference 2022 , which celebrates its 4th anniversary, will be returned both online and offline on October 1st and 2nd under the theme of Counseling Psychology and Mindfulness at the SETEC Convention Hall and via Zoom webinar.
  • The 'Seoul Relax Week Meditation Conference,' which started in 2019 to promote healthy mindfulness for the public in Seoul, has been recognized as a venue for exploring meditation and mindfulness and extending horizons of mindfulness by inviting renowned domestic and foreign experts.
  • Visit the official website ( www.relaxweek.kr ) for more information on the Seoul Relax Week 2022 Meditation Conference; ticket sales have been open now.
  • The Seoul Relaxation Week 2022 is an online and offline festival that promotes mental health & healing.

United States Behavioral Health EHR Market Trends/Analysis Report 2022: A $459 Million market by 2030 - Government Initiatives to Promote EHR Adoption - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022

The "U.S. Behavioral Health EHR Market Size, Share & Trends Analysis Report by End Use (State-owned, Private), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Behavioral Health EHR Market Size, Share & Trends Analysis Report by End Use (State-owned, Private), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. behavioral health EHR market size is expected to reach USD 459.1 million by 2030.
  • With clinical and financial consequences at stake, behavioral care practitioners are adopting health IT solutions such as EHR technology at a faster rate than that in previous years.
  • Positive patient perception toward hospitals is boosting the adoption of EHR among behavioral care providers.

Short-Term Study of Ecopipam Shows Reduction of Tics in Children with Tourette Syndrome

Retrieved on: 
Thursday, September 15, 2022

MILWAUKEE, Sept. 15, 2022 /PRNewswire-PRWeb/ -- A recent study evaluated the efficacy and safety of a pharmaceutical treatment, ecopipam, for children with Tourette syndrome (TS), according to a study released today at the International Congress of Parkinson's Disease and Movement Disorders® in Madrid, Spain. (Mahableshwarkar et al., 2022)

Key Points: 
  • MILWAUKEE, Sept. 15, 2022 /PRNewswire-PRWeb/ -- A recent study evaluated the efficacy and safety of a pharmaceutical treatment, ecopipam, for children with Tourette syndrome (TS), according to a study released today at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain.
  • Importantly, ecopipam is known for having a low incidence of adverse effects and was well-tolerated during the study.
  • The double-blind study lasted 12 weeks and examined children with Tourette's ranging from 6 to 17 years old.
  • Overall, this phase 2b study generates hope and supports that ecopipam deserves further investigation as a new treatment option for tics in TS."

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™

Retrieved on: 
Wednesday, September 14, 2022

Cigna will be issuing an updated revision to its TMS medical coverage policy effective September 15, 2022extending coverage to patients aged 18 and older diagnosed with OCD.

Key Points: 
  • Cigna will be issuing an updated revision to its TMS medical coverage policy effective September 15, 2022extending coverage to patients aged 18 and older diagnosed with OCD.
  • OCD is a difficult to treat disease, and almost half of the patients with OCD are treatment-resistant.
  • This positive coverage decision supplements the growing body of compelling clinical evidence supporting the treatment of OCD with our Deep TMS H7 Coil.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony

Retrieved on: 
Tuesday, September 13, 2022

The curriculum offered at NeuroStar University has three components: Learn, Connect, and Grow.

Key Points: 
  • The curriculum offered at NeuroStar University has three components: Learn, Connect, and Grow.
  • Currently, NeuroStar University is offering two-day classes at no charge to existing NeuroStar practices.For more information about NeuroStar, please visit neurostar.com .
  • As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health.
  • NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered.

Identification of Symptom-Specific Brain Circuit Abnormalities in Obsessive-Compulsive Disorder

Retrieved on: 
Thursday, September 1, 2022

New York, Sept. 01, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, Identification of Symptom-Specific Brain Circuit Abnormalities in Obsessive-Compulsive Disorder on Tuesday, September 13, 2022, at 2:00 pm EDT.

Key Points: 
  • New York, Sept. 01, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, Identification of Symptom-Specific Brain Circuit Abnormalities in Obsessive-Compulsive Disorder on Tuesday, September 13, 2022, at 2:00 pm EDT.
  • Register today at BBRFoundation.org
    Individuals with obsessive-compulsive disorder (OCD) experience a wide array of different types of obsessions and compulsions.
  • The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness.
  • These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia, as well as research on suicide prevention.